Incyte受益于PD-1抑制剂强劲需求，一季度业绩超预期

环球市场播报04-28

Incyte公布的2026年第一季度财报显示，得益于核心药物及癌症治疗组合的强劲需求，公司业绩超出了华尔街分析师的普遍预期。　　财报数据显示，Incyte本季度总收入实现了同比增长，主要驱动力来自其重磅药物以及与日本武田制药合作的资产。Incyte的核心产品销售增长显著，同时其他商业资产的专营权使用费收入也持续向好。例如，PD-1抑制剂的强劲需求对公司业绩产生了积极影响。　　受此利好消息影响，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2630946589?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-04-28 23:30","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2630946589","market":"fut","top_or_hot":-1,"title":"Incyte受益于PD-1抑制剂强劲需求，一季度业绩超预期","media":"环球市场播报","content":"<div>\n<p>Incyte公布的2026年第一季度财报显示，得益于核心药物及癌症治疗组合的强劲需求，公司业绩超出了华尔街分析师的普遍预期。\n　　财报数据显示，Incyte本季度总收入实现了同比增长，主要驱动力来自其重磅药物以及与日本武田制药合作的资产。Incyte的核心产品销售增长显著，同时其他商业资产的专营权使用费收入也持续向好。例如，PD-1抑制剂的强劲需求对公司业绩产生了积极影响。\n　　受此利好消息影响，...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/usstock/c/2026-04-28/doc-inhwapms8394113.shtml\">网页链接</a>\n\n</div>\n","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Incyte受益于PD-1抑制剂强劲需求，一季度业绩超预期</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIncyte受益于PD-1抑制剂强劲需求，一季度业绩超预期\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-28 23:30 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/stock/usstock/c/2026-04-28/doc-inhwapms8394113.shtml><strong>环球市场播报</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Incyte公布的2026年第一季度财报显示，得益于核心药物及癌症治疗组合的强劲需求，公司业绩超出了华尔街分析师的普遍预期。\n　　财报数据显示，Incyte本季度总收入实现了同比增长，主要驱动力来自其重磅药物以及与日本武田制药合作的资产。Incyte的核心产品销售增长显著，同时其他商业资产的专营权使用费收入也持续向好。例如，PD-1抑制剂的强劲需求对公司业绩产生了积极影响。\n　　受此利好消息影响，...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/usstock/c/2026-04-28/doc-inhwapms8394113.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1169589451.USD","symbol_name":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","start_time":0,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-04-28/doc-inhwapms8394113.shtml","article_id":"2630946589","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2630946589","pubTimestamp":1777390200,"columns":[],"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"Incyte公布的2026年第一季度财报显示，得益于核心药物及癌症治疗组合的强劲需求，公司业绩超出了华尔街分析师的普遍预期。　　财报数据显示，Incyte本季度总收入实现了同比增长，主要驱动力来自其重磅药物以及与日本武田制药合作的资产。Incyte的核心产品销售增长显著，同时其他商业资产的专营权使用费收入也持续向好。　　基于第一季度的超预期表现，Incyte重申了其2026年全年的业绩指引，预计市场对其创新药物的需求将保持稳定。","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","PD":"PagerDuty, Inc.","BK4023":"应用软件"},"translate_title":"Incyte benefits from strong demand for PD-1 inhibitors, first-quarter results beat expectations","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PD":1.5},"content_text":"Incyte公布的2026年第一季度财报显示，得益于核心药物及癌症治疗组合的强劲需求，公司业绩超出了华尔街分析师的普遍预期。\n　　财报数据显示，Incyte本季度总收入实现了同比增长，主要驱动力来自其重磅药物以及与日本武田制药合作的资产。Incyte的核心产品销售增长显著，同时其他商业资产的专营权使用费收入也持续向好。例如，PD-1抑制剂的强劲需求对公司业绩产生了积极影响。\n　　受此利好消息影响，Incyte股价在盘前交易中应声上涨。相比之下，其竞争对手百时美施贵宝和医疗器械公司捷迈邦美也定于本周发布财报，投资者正密切关注行业动向。\n　　基于第一季度的超预期表现，Incyte重申了其2026年全年的业绩指引，预计市场对其创新药物的需求将保持稳定。公司高管在声明中表示，对在研管线的进展及核心业务的商业执行力充满信心。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2630946589","isCrawlerRequest":true}